This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomePrevnar 20®Prevnar 20®Serotypes matterAdministrationBurden of diseaseBurden
of diseasePneumococcal pneumoniaLinked Mega MenuBurden
of diseaseLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkIPDPatient profilesPatient
profilesAge 50+DiabetesAsthmaCOPDChronic heart diseaseRisk for all underlying medical conditionsClinical studiesClinical studiesBuilt on PCV13CAPiTAStudy 1 designStudy 1 resultsStudy 1 safetyStudy 6 designStudy 6 resultsStudy 6 safetyCDC recommendationsAccess & supportAccess & supportMedicareCommercial health plansMaterialsVideos
Prescribing InformationIndicationsPatient SiteOrder Prevnar 20®
Chronic heart disease puts adult patients at greater risk1Adults aged 18 to 49 with CHD are at 3.7x greater risk for pneumococcal pneumonia2,3**Compared with healthy adults aged 18 to 49.2,310.2x more likely to contract IPD2
  • The CDC recommends Prevnar 20® for:
    • Eligible adult patients aged 19+ with chronic heart disease1
    • Both vaccine-naïve† and previously vaccinated‡ eligible adults who are at increased risk for pneumococcal pneumonia1
      ‡Patients aged 19 to 49 years with chronic conditions§ who have received PPSV23 only or PCV13 only 1+ years ago are eligible for PCV20 or PCV21. PCV15 is an option if these individuals received PPSV23 alone 1+ years ago.1
  • AHA, ACC, and HFSA recommend adult patients with heart failure be vaccinated against respiratory illnesses according to their 2022 guidelines4¶
Prevnar 20 completes the CDC recommendation in one dose for ALL eligible adult patients.1,5 Vaccinate today.
View risk data for pneumococcal pneumonia View risk chart LoadingReferences:ACC=American College of Cardiology; AHA=American Heart Association; CDC=Centers for Disease Control and Prevention; CHD=chronic heart disease; COPD=chronic obstructive pulmonary disease; HFSA=Heart Failure Society of America; IPD=invasive pneumococcal disease; PCV7=7-valent pneumococcal conjugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine.
†Also applies to people who received PCV7 at any age and have received no other pneumococcal vaccines.1

§Chronic conditions include alcoholism, chronic heart disease (including congestive heart failure and cardiomyopathies), chronic liver disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), cigarette smoking, and diabetes mellitus.1

This is a moderate recommendation with moderate-quality evidence from 1 or more well-designed, well-executed, nonrandomized studies, observational studies, or registry studies.4 References:Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile supplementary data. Open Forum Infect Dis. 2023;10(5):S1-S35.  Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023. Patient ProfilesDownload CDC recommendations for 50+ DownloadLoadingOrder Prevnar 20 for your office by registering for Prime Get started LoadingReferences:CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; PCV13=13-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine; PCV20=20-valent pneumococcal conjugate vaccine; PCV21=21-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine *[Footnote TK.^X] †Based on shared clinical decision-making, vaccine providers may choose to administer Prevnar 20 to adults aged ≥65 years who received PCV13 but not PCV15, PCV20, or PCV21 at any age and PPSV23 at age ≥65 at least 5 years ago.5 References:Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793-798. [Reference TK.] Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile. Open Forum Infect Dis. 2023;10(5):ofad192. Grant LR, Meche A, McGrath L, et al. Risk of pneumococcal disease in US adults by age and risk profile supplementary data. Open Forum Infect Dis. 2023;10(5):S1-S35.  Centers for Disease Control and Prevention. Pneumococcal vaccine timing for adults. October 2024. Accessed November 13, 2024. https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-3105 © 2025 Pfizer Inc.
All rights reserved. September 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-3105
You are now leaving PfizerPro You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-MCL-USA-0367
INDICATION AND SELECT SAFETY INFORMATION
  • Prevnar 20® is a vaccine approved for:​​​​​
    • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
    • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial
SELECT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • In individuals 18 years of age and older, the most commonly reported solicited adverse reactions (>10%) were pain at the injection site, muscle pain, fatigue, headache, and arthralgia. Additionally, injection site swelling was also reported (>10%) in individuals 18 through 59 years of age
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATION
  • Prevnar 20® is a vaccine approved for:
    • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
    • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older
  • The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial